CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

NCT03298828 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Burkitt Lymphoma

Interventions

BIOLOGICAL: CD19 CAR and PD-1 knock out engineered T-cells
BIOLOGICAL: CD19 CAR T-cells

Sponsor

Third Military Medical University